Predictive parameters of body weight reduction for responders and non-responders after dapagliflozin treatment
| Variable | Responder (N=23) |
Non-responder (N=34) |
|
|---|---|---|---|
| Age (yr) | 59.2±9.4 | 57.8±10.0 | 0.684 |
| DM duration (yr) | 11.0±5.4 | 12.3±5.6 | 0.357 |
| BMI (kg/m2) | 27.4±18.3 | 27.0±3.0 | 0.922 |
| C-peptide (ng/mL) | 3.25±1.07 | 2.62±1.02 | 0.023 |
| Insulin (μIU/mL) | 13.6±5.9 | 11.4±7.5 | 0.064 |
| HOMA-IR | 5.4±2.3 | 5.4±5.8 | 0.074 |
| HOMA-β | 60.1±48.8 | 49.4±40.0 | 0.283 |
Values are presented as mean±standard deviation.
Responder is defined patients who achieved ≥5% body weight reduction. Non-responder is classified those who achieved <5% body weight reduction.
HOMA-IR, [FPI (μIU/ml)×FPG (mmol/L)]/22.5; HOMA-β, [20×FPI (μIU/ml)]/[FPG (mmol/L)-3.5.
Yr, year; DM, diabetes mellitus; BMI, body mass index; HOMA-IR, homeostatic model assessment-insulin resistant; HOMA-β, homeostatic model assessment-beta cell function; FPI, fasting plasma insulin; FPG, fasting plasma glucose.